secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0000950170-23-068798
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome hosts solriamfetol investor day with expert panel covering MDD, ADHD, BED, and sleep disorders
--------------------------------------------------------------------------------

- Virtual investor event held Dec 7, 2023, featuring five physician thought leaders discussing solriamfetol.
- Indications covered: MDD, ADHD, binge eating disorder, OSA/EDS (SHARP study), and shift work disorder.
- Axsome management provided overview of clinical development plans for solriamfetol.
- No specific clinical data, financial results, or pipeline milestones disclosed in the press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023068798/0000950170-23-068798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023068798/axsm-20231207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-068798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer